IL300113A - Compressed cyclic RAF inhibitors and methods of using them - Google Patents
Compressed cyclic RAF inhibitors and methods of using themInfo
- Publication number
- IL300113A IL300113A IL300113A IL30011323A IL300113A IL 300113 A IL300113 A IL 300113A IL 300113 A IL300113 A IL 300113A IL 30011323 A IL30011323 A IL 30011323A IL 300113 A IL300113 A IL 300113A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- fused bicyclic
- raf inhibitors
- raf
- inhibitors
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057536P | 2020-07-28 | 2020-07-28 | |
| PCT/EP2021/071212 WO2022023447A2 (en) | 2020-07-28 | 2021-07-28 | Fused bicyclic raf inhibitors and methods for use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300113A true IL300113A (en) | 2023-03-01 |
Family
ID=77499800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300113A IL300113A (en) | 2020-07-28 | 2021-07-28 | Compressed cyclic RAF inhibitors and methods of using them |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11858930B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4188552A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023535790A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230058399A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116601150A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021314955A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023001557A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3187514A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300113A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001275A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022023447A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11858930B2 (en) | 2020-07-28 | 2024-01-02 | Jazz Pharmaceuticals Ireland Limited | Fused bicyclic RAF inhibitors and methods for use thereof |
| CN116143633B (zh) * | 2022-12-30 | 2026-05-26 | 浙江巍华新材料股份有限公司 | 一种制备2,5-二氯-4-三氟甲基苯胺的方法 |
| US20260232643A1 (en) * | 2023-02-17 | 2026-08-13 | Jazz Pharmaceuticals Ireland Limited | Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations |
| WO2024210578A1 (ko) * | 2023-04-05 | 2024-10-10 | 주식회사 바오밥에이바이오 | 헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3932657A (en) | 1973-11-12 | 1976-01-13 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome encapsulation of chelating agents |
| GB1575343A (en) | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452747A (en) | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
| JPS6058915A (ja) | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
| US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4830858A (en) | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| JPH0617309B2 (ja) | 1985-11-29 | 1994-03-09 | 株式会社ビタミン研究所 | アドリアマイシン包埋リポソ−ム製剤 |
| DE3611229A1 (de) | 1986-04-04 | 1987-10-08 | Basf Ag | Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinoidpraeparaten |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| US5698550A (en) | 1993-06-14 | 1997-12-16 | Pfizer Inc. | Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases |
| JP2930421B2 (ja) | 1994-02-28 | 1999-08-03 | メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物、その製造方法及びその使用方法 |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| EP0825852B1 (en) | 1995-04-18 | 2004-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
| US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US8137699B2 (en) | 2002-03-29 | 2012-03-20 | Trustees Of Princeton University | Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use |
| FI20011507A0 (fi) | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
| EP1432403B1 (en) | 2001-10-03 | 2010-07-28 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| US20050118250A1 (en) | 2001-11-13 | 2005-06-02 | Paul Tardi | Lipid carrier compositions with enhanced blood stability |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| CN1690056A (zh) | 2004-04-30 | 2005-11-02 | 北京大学 | 三个化合物及其制备方法和用途 |
| GB0503506D0 (en) | 2005-02-21 | 2005-03-30 | 4 Aza Bioscience Nv | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2007067444A1 (en) | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| WO2008009079A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| EP2167497A2 (en) * | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| DK2797888T3 (en) | 2011-12-31 | 2016-09-19 | Beigene Ltd | Fused tricyclic compounds as RAF kinase inhibitors |
| GB201416186D0 (en) * | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| CN109503659B (zh) | 2019-01-03 | 2021-06-18 | 凯特立斯(深圳)科技有限公司 | 氧杂螺环双膦配体及其在α,β-不饱和羧酸不对称氢化中的应用 |
| IL300110A (en) | 2020-07-28 | 2023-03-01 | Jazz Pharmaceuticals Ireland Ltd | Chiral synthesis of fused bicyclic raf inhibitors |
| US11858930B2 (en) | 2020-07-28 | 2024-01-02 | Jazz Pharmaceuticals Ireland Limited | Fused bicyclic RAF inhibitors and methods for use thereof |
-
2021
- 2021-07-28 US US17/387,049 patent/US11858930B2/en active Active
- 2021-07-28 KR KR1020237006991A patent/KR20230058399A/ko active Pending
- 2021-07-28 CA CA3187514A patent/CA3187514A1/en active Pending
- 2021-07-28 JP JP2023505743A patent/JP2023535790A/ja active Pending
- 2021-07-28 MX MX2023001275A patent/MX2023001275A/es unknown
- 2021-07-28 EP EP21759247.6A patent/EP4188552A2/en active Pending
- 2021-07-28 AU AU2021314955A patent/AU2021314955A1/en active Pending
- 2021-07-28 BR BR112023001557A patent/BR112023001557A2/pt unknown
- 2021-07-28 WO PCT/EP2021/071212 patent/WO2022023447A2/en not_active Ceased
- 2021-07-28 IL IL300113A patent/IL300113A/en unknown
- 2021-07-28 CN CN202180066002.9A patent/CN116601150A/zh active Pending
-
2023
- 2023-11-16 US US18/511,344 patent/US12304912B2/en active Active
-
2025
- 2025-05-12 US US19/205,876 patent/US20260092063A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022023447A3 (en) | 2022-03-10 |
| US20220033398A1 (en) | 2022-02-03 |
| US20260092063A1 (en) | 2026-04-02 |
| EP4188552A2 (en) | 2023-06-07 |
| JP2023535790A (ja) | 2023-08-21 |
| CA3187514A1 (en) | 2022-02-03 |
| KR20230058399A (ko) | 2023-05-03 |
| BR112023001557A2 (pt) | 2023-04-04 |
| CN116601150A (zh) | 2023-08-15 |
| AU2021314955A1 (en) | 2023-03-30 |
| MX2023001275A (es) | 2023-04-24 |
| US11858930B2 (en) | 2024-01-02 |
| WO2022023447A2 (en) | 2022-02-03 |
| US20240124452A1 (en) | 2024-04-18 |
| US12304912B2 (en) | 2025-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106977PA (en) | Polypeptides useful for gene editing and methods of use | |
| IL261625B (en) | Inhibitors of menin-mll in bridged cycles and methods of use | |
| SG11202104355SA (en) | Methods for selection and stimulation of cells and apparatus for same | |
| PL3711730T3 (pl) | Wyroby chłonne i sposoby wytwarzania | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| IL289952A (en) | Anti-ms4a4a antibodies and methods of using them | |
| IL264854A (en) | Spt5 inhibitors and methods of use thereof | |
| IL290741A (en) | Antibodies against cd-96 and methods of using them | |
| IL270792B1 (en) | Methods for the preparation and use of pde9 inhibitors | |
| SG11202109593SA (en) | T cell receptors and methods of use thereof | |
| SG11202109588RA (en) | T cell receptors and methods of use thereof | |
| SG11202109595TA (en) | T cell receptors and methods of use thereof | |
| SG11202109591QA (en) | T cell receptors and methods of use thereof | |
| SG11202109589VA (en) | T cell receptors and methods of use thereof | |
| SG11202109590VA (en) | T cell receptors and methods of use thereof | |
| IL288886A (en) | Antibodies and methods of use | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of using them | |
| IL312466A (en) | PI3K-alpha inhibitors and methods for their preparation and use | |
| SG11202109594PA (en) | T cell receptors and methods of use thereof | |
| SG11202011267XA (en) | Apparatus and method of use thereof | |
| IL276053A (en) | Therapeutic Gard and methods of its use | |
| PL3975780T3 (pl) | Cholewa i sposób wytwarzania cholewy | |
| IL290221A (en) | T-cell receptors and methods for their use | |
| IL290228A (en) | T-cell receptors and methods for their use |